Table 1.
Clinical trials that use or affect regulatory T cells.
| A) ongoing/recruiting/planned clinical trials | |||||
|---|---|---|---|---|---|
| all diseases | GvHD | transplantation | autoimmune diseases | other* | |
| all interventions | 109 | 14 | 23 | 55 | 17 |
| polyspecific Tregs | 29 | 7 | 10 | 10 | 2 |
| redirected Tregs | 3 | – | 2** (17, 18) | – | 1 |
| converted Tregs | 1 | – | – | 1 | – |
| in vivo Treg stimulation | 76 | 7 | 11 | 44 | 14 |
| B) completed clinical trials | |||||
| all diseases | GvHD | transplantation | autoimmune diseases | other* | |
| all interventions | 160 | 12 | 19 | 102 | 27 |
| polyspecific Tregs | 16 | 5 | 7 (19) | 2 (20) | 2 |
| redirected Tregs | – | – | – | – | – |
| converted Tregs | – | – | – | – | – |
| in vivo Treg stimulation | 144 | 7 | 12 | 100 | 25 |
*other: allergy, infections, cancer, pregnancy, other rare diseases etc.
** HLA-A2 specific CAR Tregs
(source: clinicaltrials.gov, search term “regulatory t cells”, record date 2022-06-28)